aTyr Pharma Inc (LIFE.OQ)
LIFE.OQ on NASDAQ Stock Exchange Global Select Market
2.40USD
20 Apr 2018
2.40USD
20 Apr 2018
Change (% chg)
$-0.05 (-2.04%)
$-0.05 (-2.04%)
Prev Close
$2.45
$2.45
Open
$2.45
$2.45
Day's High
$2.45
$2.45
Day's Low
$2.40
$2.40
Volume
4,250
4,250
Avg. Vol
8,293
8,293
52-wk High
$6.45
$6.45
52-wk Low
$2.33
$2.33
About
aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based... (more)
Overall
| Beta: | -- |
| Market Cap(Mil.): | $75.88 |
| Shares Outstanding(Mil.): | 29.76 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| LIFE.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 185.16 | 33.25 |
| EPS (TTM): | -1.89 | -- | -- |
| ROI: | -63.87 | -0.71 | 13.13 |
| ROE: | -75.89 | -2.76 | 14.96 |
BRIEF-Atyr Pharma Q4 Loss Per Share $0.39
* ATYR PHARMA ANNOUNCES FOURTH QUARTER AND YEAR-END 2017 OPERATING RESULTS AND PROVIDES CORPORATE UPDATE
BRIEF-Atyr Pharma Says On Dec 22, Co Entered Into Amendment To Loan And Security Agreement Dated As Of Nov 18, 2016
* ATYR PHARMA SAYS ON DEC 22, CO ENTERED INTO AMENDMENT TO LOAN AND SECURITY AGREEMENT DATED AS OF NOV 18, 2016 - SEC FILING
BRIEF-aTyr Pharma reports qtrly net loss per share, basic and diluted $0.43
* aTyr Pharma announces third quarter 2017 operating results and provides corporate update
Estimates